Quick Answer
OnKure Therapeutics, Inc. reported Stockholders Equity of $56.18 million for the year ending 2025.
- OnKure Therapeutics, Inc. showed a decrease of -45.9% in Stockholders Equity from 2024 to 2025.
- This data is from OnKure Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$27.43 million | Q2 2020: -$31.04 million | Q3 2020: -$36.00 million | Q1 2021: -$48.72 million | Q2 2021: $167.55 million | Q3 2021: $156.21 million | Q1 2022: $135.32 million | Q2 2022: $124.16 million | Q3 2022: $112.05 million | Q1 2023: $87.08 million | Q2 2023: $132.53 million | Q3 2023: $114.94 million | Q1 2024: -$111.26 million | Q2 2024: -$123.58 million | Q3 2024: -$135.05 million | Q1 2025: $90.65 million | Q2 2025: $78.17 million | Q3 2025: $66.43 million.
- Over the full 7 years of available data (2019 to 2025), OnKure Therapeutics, Inc.'s Stockholders Equity has grown by 342.9%.
- Historical annual values: Fiscal year 2025: $56.18 million | Fiscal year 2024: $103.83 million | Fiscal year 2023: -$101.84 million | Fiscal year 2022: -$54.42 million | Fiscal year 2021: $147.21 million | Fiscal year 2020: -$42.12 million | Fiscal year 2019: -$23.13 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: